AI Stock Analysis - ATAI Life Sciences (ATAI)
Analysis generated October 10, 2025.
ATAI Life Sciences is a clinical-stage biopharmaceutical company focused on developing novel treatments for mental health disorders. Utilizing a decentralized approach, ATAI collaborates with various subsidiary companies to leverage the most promising advancements in neuropsychiatry. With the increasing awareness and investment in mental health solutions, the company is positioned at a critical juncture in this dynamic sector.
Stock Alerts - ATAI Life Sciences (ATAI)
 |
ATAI Life Sciences | March 12 Price is down by -6% in the last 24h. |
|
ATAI Life Sciences | March 10 Price is up by 6% in the last 24h. |
|
ATAI Life Sciences | March 9 Price is up by 10% in the last 24h. |
|
ATAI Life Sciences | March 5 Price is down by -6.2% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for ATAI Life Sciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 98 | Sign up | Sign up | Sign up |
| Webpage traffic | 16,000 | Sign up | Sign up | Sign up |
| Employee Rating | 94 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Instagram Followers | 142,743 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 186 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,719 | Sign up | Sign up | Sign up |
| X Followers | 13,408 | Sign up | Sign up | Sign up |
| X Mentions | 75 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 94 | Sign up | Sign up | Sign up |
| Linkedin Employees | 96 | Sign up | Sign up | Sign up |
About ATAI Life Sciences
atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, with offices in New York, San Diego and Berlin.
| Price | $3.69 |
| Target Price | Sign up |
| Volume | 9,159,528 |
| Market Cap | $1.34B |
| Year Range | $2.62 - $6.45 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Psychedelic Drugs Market Trends and Global Forecasts Report 2026-2035: 45+ Developers Advance Ketamine and Psilocybin Therapies with Expanding Clinical Trials and Rising Regulatory MomentumMarch 12 - GlobeNewswire |
|
AtaiBeckley shares are trading higher after the company said it will initiate Phase 3 trial of BPL‑003 in Q2 2026 following end-of-phase 2 meeting with the FDA. Also, the company reaffirmed its cash runway through the planned early-2029 topline readouts from both parallel Phase 3 pivotal studies.March 9 - Benzinga |
|
 |
AtaiBeckley: Lead Candidate Could Be Game-Changer For TRD Patients, Say AnalystsMarch 9 - Benzinga |
AtaiBeckley To Initiate Phase 3 Trial Of BPL‑003 (Mebufotenin Benzoate Nasal Spray) In Q2 2026 Following End-Of-Phase 2 Meeting With The FDA, Cash Runway Reaffirmed Through The Planned Early-2029March 9 - Benzinga |
|
 |
4 Analysts Have This To Say About AtaiBeckleyMarch 8 - Benzinga |
Needham Reiterates Buy on AtaiBeckley, Maintains $14 Price TargetMarch 8 - Benzinga |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 750,000 | 0 | 750,000 | -61M | -61M | -0.280 |
| Q2 '25 | 720,000 | 0 | 720,000 | -28M | -27M | -0.140 |
| Q1 '25 | 1.6M | 11M | -9.3M | -26M | -19M | -0.150 |
| Q4 '24 | -5,000 | 170,000 | -5,000 | -39M | -38M | -0.240 |
| Q3 '24 | 40,000 | 0 | 40,000 | -26M | -26M | -0.160 |
Insider Transactions View All
| Apeiron Investment Group Ltd. filed to buy 51,045,214 shares at $2.2. August 18 '25 |
| Apeiron Investment Group Ltd. filed to buy 42,369,415 shares at $1.4. March 24 '25 |
| Short Glenn Frank filed to sell 42,333 shares at $1.4. March 24 '25 |
| Johnson Anne Nagengast filed to sell 140,045 shares at $1.4. March 24 '25 |
| Rao Srinivas filed to sell 212,942 shares at $1.4. March 24 '25 |
Similar companies
Read more about ATAI Life Sciences (ATAI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - ATAI Life Sciences
The Market Cap of ATAI Life Sciences is $1.34B.
Currently, the price of one share of ATAI Life Sciences stock is $3.69.
The ATAI stock price chart above provides a comprehensive visual representation of ATAI Life Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling ATAI Life Sciences shares. Our platform offers an up-to-date ATAI stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, ATAI Life Sciences (ATAI) does not offer dividends to its shareholders. Investors interested in ATAI Life Sciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of ATAI Life Sciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
